Market Place
Sourcing Support
Bluebird Joins CMMI Cell & Gene Therapy Access Model
04 Dec 2024 //
BUSINESSWIRE
bluebird bio Announces 1-for-20 Reverse Stock Split
04 Dec 2024 //
BUSINESSWIRE
FDA considers `regulatory action` for bluebird`s Skysona
03 Dec 2024 //
FIERCE PHARMA
FDA probes blood cancer risk from bluebird`s gene therapy
29 Nov 2024 //
REUTERS
bluebird bio Reports Q3 2024 Results & 2024 Guidance
14 Nov 2024 //
BUSINESSWIRE
bluebird bio Adjourns Stockholder Meeting, Announces Q3 Results
06 Nov 2024 //
BUSINESSWIRE
bluebird bio to Present Gene Therapy Data at ASH 2024
05 Nov 2024 //
BUSINESSWIRE
bluebird bio Reports Inducement Grants Under Nasdaq Rule
04 Oct 2024 //
BUSINESSWIRE
Bluebird Restructures to Optimize Cost Structure and Cash Runway
24 Sep 2024 //
CONTRACTPHARMA
bluebird bio Announces Receipt of Expected Notices from Nasdaq
23 Aug 2024 //
BUSINESSWIRE
Bluebird Hit With Slow Uptake of Sickle Cell, Beta-Thalassemia Gene Therapies
16 Aug 2024 //
BIOSPACE
Bluebird Stock Falls 18% On Slow Lyfgenia Gene Therapy Uptake
14 Aug 2024 //
FIERCE PHARMA
bluebird bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
02 Aug 2024 //
BUSINESSWIRE
Bluebird bio`s gene therapy fertility support program gets thumbs down from HHS
22 Jul 2024 //
FIERCE PHARMA
bluebird Reports Inducement Grant to CFO Sterling Under Nasdaq Listing Rule
03 Jul 2024 //
BUSINESSWIRE
Neurocrine CEO Retires, Bluebird Appoints 5th CFO In 3 Years
31 May 2024 //
ENDPTS
bluebird bio Appoints O. James Sterling as Chief Financial Officer
29 May 2024 //
BUSINESSWIRE
BLUE Investor Alert: Kirby McInerney Notes Lead Plaintiff Deadline
17 May 2024 //
BUSINESSWIRE
Bluebird bio starts 15 patients on its three multimillion-dollar gene therapies
09 May 2024 //
ENDPTS
With 64 centers activated, bluebird is ready to grow Lyfgenia
09 May 2024 //
FIERCE PHARMA
bluebird First Cell Collection For LYFGENIA Gene Therapy
06 May 2024 //
BUSINESSWIRE
Vertex touts Casgevy sickle cell launch as bluebird makes progress Lyfgenia
06 May 2024 //
ENDPTS
bluebird bio schedules first quarter 2024 results call.
06 May 2024 //
BUSINESSWIRE
bluebird bio Announces Receipt of Expected Notice from Nasdaq
26 Apr 2024 //
BUSINESSWIRE
bluebird bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
11 Apr 2024 //
BUSINESSWIRE
bluebird bio Reports Fourth Quarter and 2023 Annual Results
26 Mar 2024 //
BUSINESSWIRE
Bluebird discusses Lyfgenia launch details and accounting errors
26 Mar 2024 //
FIERCE PHARMA
bluebird bio Secures up to $175 Million Debt Financing with Hercules Capital
18 Mar 2024 //
BUSINESSWIRE
Bluebird secures $175M loan from Hercules Capital
18 Mar 2024 //
FIERCE PHARMA
bluebird bio Announces First Outcomes-Based Agreement with Medicaid
11 Mar 2024 //
BUSINESSWIRE
Michigan Medicaid signs deal with bluebird for SCD gene therapy
11 Mar 2024 //
FIERCE PHARMA
JPM24: Bluebird CEO defends Lyfgenia pricing premium, EU retreat
10 Jan 2024 //
FIERCE PHARMA
Bluebird is looking for financing as it brings sickle cell therapy to market
10 Jan 2024 //
ENDPTS
Blueprint to pull Gavreto in certain markets
09 Jan 2024 //
ENDPTS
bluebird bio Provides Update on Commercial Launch Progress
08 Jan 2024 //
BUSINESSWIRE
Bluebird snags more outcomes-based coverage for $3M+ sickle cell gene therapy
04 Jan 2024 //
ENDPTS
bluebird bio to Present at the 42nd Annual J.P. Morgan Healthcare Conference
02 Jan 2024 //
BUSINESSWIRE
Bluebird quickly raises funds to support gene therapy launches
19 Dec 2023 //
FIERCE PHARMA
bluebird bio, Inc. Announces Proposed Public Offering of Common Stock
18 Dec 2023 //
BUSINESSWIRE
Bluebird signs pact with insurer for sickle cell gene therapy
15 Dec 2023 //
REUTERS
Data Presented Support beti-cel as Curative Gene Therapy for ?-Thalassemia
10 Dec 2023 //
BUSINESSWIRE
Data From bluebird’s Program in Sickle Cell Disease Support Durable Benefits
09 Dec 2023 //
BUSINESSWIRE
FDA Approves First Gene Therapies to Treat Patients with Sickle Cell Disease
09 Dec 2023 //
PR NEWSWIRE
Bluebird plunges after pricing sickle cell gene therapy well above competitor
08 Dec 2023 //
ENDPTS
bluebird bio to Present New and Updated Data from Gene Therapy Programs
02 Nov 2023 //
BUSINESSWIRE
bluebird bio Enters into Advance Agreement to Sell Priority Review Voucher
30 Oct 2023 //
BUSINESSWIRE
Bluebird inks deal to sell lovo-cel FDA voucher for $103M
30 Oct 2023 //
FIERCE PHARMA
Bluebird Bio to Host Third Quarter 2023 Financial Results Conference Call
24 Oct 2023 //
BUSINESSWIRE
Bluebird tweaks partnership with Lonza to boost Zynteglo
27 Sep 2023 //
ENDPTS
bluebird bio Announces September Investor Events
05 Sep 2023 //
BUSINESSWIRE
Bluebird’s Lovo-Cel Gene Therapy for SCD Will Not Face FDA Adcomm
17 Aug 2023 //
BIOSPACE
Bluebird touts gene therapy launches as cash remains tight
08 Aug 2023 //
FIERCE PHARMA
Bluebird bio to Host Second Quarter 2023 Financial Results Conference
25 Jul 2023 //
BUSINESSWIRE
U.S. watchdog lifts price estimate for Bluebird, Vertex gene therapies to $2.1 million
13 Jul 2023 //
REUTERS
Bluebird gets PDUFA date for lovo-cel; FDA lifts hold on DiaMedica stroke trial
21 Jun 2023 //
ENDPTS
bluebird bio Reports1Q 2023 FYR and Highlights Operational Progress
09 May 2023 //
BUSINESSWIRE
bluebird bio Announces 1Q 2023 Earnings Date and Upcoming Investor Events
27 Apr 2023 //
BUSINESSWIRE
Bluebird`s lovo-cel application finally lands at the FDA`s desk
24 Apr 2023 //
FIERCE PHARMA
bluebird bio Submits BLA to FDA for lovo-cel for Patients with SCD
24 Apr 2023 //
BUSINESSWIRE
Vertex, bluebird SCD gene therapies can cost $1.9M
13 Apr 2023 //
FIERCE PHARMA
